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Abstract
The decline in neuronal function during aging may result from increases in extracellular glutamate
(Glu), Glu-induced neurotoxicity, and altered mitochondrial metabolism. To study metabolic
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responses to persistently high levels of Glu at synapses during aging, we used transgenic (Tg)
mice that over-express the enzyme Glu dehydrogenase (GDH) in brain neurons and release excess
Glu in synapses. Mitochondrial GDH is important in amino acid and carbohydrate metabolism and
in anaplerotic reactions. We monitored changes in nineteen neurochemicals in the hippocampus
and striatum of adult, middle aged, and aged Tg and wild type (wt) mice, in vivo, using proton
(1H) magnetic resonance spectroscopy. Significant differences between adult Tg and wt were
higher Glu, N-acetyl aspartate (NAA), and NAA + NAA−Glu (NAAG) levels, and lower lactate in
the Tg hippocampus and striatum than those of wt. During aging, consistent changes in Tg and wt
hippocampus and striatum included increases in myo-inositol and NAAG. The levels of glutamine
(Gln), a key neurochemical in the Gln-Glu cycle between neurons and astroglia, increased during
aging in both the striatum and hippocampus of Tg mice, but only in the striatum of the wt mice.
Age-related increases of Glu were observed only in the striatum of the Tg mice.
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Introduction
The function of glutamate (Glu) as the major excitatory neurotransmitter in the mammalian
central nervous system (CNS) is well known, as are also the long-lasting effects that Glu
receptor activation may have on neuronal structure and function [1, 2]. Repeated activation
of Glu receptors can lead to long-lasting modification of synaptic activity [1, 3, 4], altered
metabolic states in neurons [2, 5–7], and the initiation of processes that may lead to neuronal
injury and death [8–13].
During aging, there is a gradual rise in extracellular Glu in the brain [14–16] and an increase
in the sensitivity of certain neurons to the cytotoxic effects of Glu [17]. A significant
decrease in the dendrite levels of the microtubule-associated protein 2 (MAP2), a marker of
dendrite structure, have been observed in the aging brain [18–20]. Based on the strong
relationship between Glu hyperactivity and decreases in MAP2 labeling in dendrites of
sensitive neurons [21–25], the MAP2 decreases may be considered an index of the effects of
a hyper-glutamatergic state in the aging brain. Neurodegeneration induced by high levels of
extrasynaptic Glu is associated with changes in synaptic and dendritic morphology and in
the levels of many synapse-associated proteins, MAP2 being simply one such dendrite and
synapse-related protein [26, 27]. Most studies of neurochemical changes associated with
aging have been focused on changes in the levels of the neurotransmitters acetylcholine, 5-
hydroxytryptamine, dopamine, and nor-epinephrine [28–30] or on the age-related changes in
glucose metabolism [31, 32]. However, only few studies have been focused on Glu
metabolism by neurons and glia in brain during aging [33].
One approach for studying the neuronal responses to persistently high levels of
glutamatergic activity at synapses is the use of transgenic (Tg) or null mutant animals with
altered Glu metabolism and release or re-uptake. Null mutant mice for the high affinity glial
Glu transporter genes have high levels of extracellular Glu and suffer extensive brain
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damage and embryonic lethality [34–36]. Null mutants for the gene Tsc1 that controls the
expression and function of Glu transporters in the CNS, also maintain high baseline, non-
stimulated extracellular Glu levels and suffer from extensive neuronal damage, intractable
seizures, and have markedly shorter lifespan [37]. Thus, animals with decreased expression
of Glu transporter genes in the CNS are not suitable for studying aging-related changes in
brain metabolism resulting from excess Glu activity.
Alternatively, Tg mice over-expressing the gene for Glu dehydrogenase 1 (Glud1), a
mitochondrial matrix enzyme, only in CNS neurons have elevated levels of Glu in brain,
presumably the result of increases in intracellular Glu as baseline extracellular Glu is only
modestly and non-significantly increased [40]. These mice transiently release excess Glu at
synapses and exhibit age-related neuronal degeneration [38, 39]. However, the synaptic and
neuronal cell losses are confined to select groups of neurons, for example, the pyramidal
cells of the CA1 but not those of the CA3 region of the hippocampus, or the striatal but not
the cerebellar neurons [38, 39]. Because these Glud1 Tg mice have a lifespan that is close to
normal for C57BL/6 mice (Hui et al. unpublished observations), they may be a useful model
for studying changes in metabolic processes, as well as molecular signaling, cell structure,
synaptic activity, and electrical properties of neurons during aging.
As described by Plaitakis et al. [41], the enzyme Glu dehydrogenase (GDH) is a crucial
enzyme in “linking amino acid and carbohydrate metabolism” and contributing to “Krebs
cycle anaplerotic mechanisms”. Thus, over-expression of GDH in brain throughout the
lifespan of an organism may have profound effects on not only glutamate metabolism, but
on cellular metabolism of amino acids and carbohydrates, as well as on mitochondrial and
cellular bioenergetics. Magnetic resonance spectroscopy (MRS) is a non-invasive procedure
that can be used to measure metabolites in the living brain [42, 43]. In the present study, we
used proton 1H MRS to obtain in vivo measurements of nineteen neurochemicals in two
selected brain regions, the hippocampus and striatum. These measurements were obtained in
wild type (wt) and Glud1 Tg mice during the aging process. Our goal was to determine
whether the Glud1 Tg mice undergo a differential pattern of age-related changes in specific
metabolites in brain that might be ascribed to GDH hyperactivity, over-stimulation of Glu
receptors, or an adaptation to both excess GDH and Glu neurotransmitter activity.
Methods
Experimental Animals
The procedure for generating the Glud1 Tg mice was detailed previously [38]. Age-matched
wt mice of the same genetic background (C57BL/6) were used as the controls. All animals
were housed in a 12 h light/dark cycle with food and water ad libitum. All animal
procedures were performed in accordance with guidelines established by the Institutional
Animal Care and Use Committee (IACUC) of the University of Kansas and the University
of Kansas Medical Center. The MRS data analyses of neurochemicals were obtained from
three mouse groups at the following three age ranges: adult i.e., 8–12.5 month old, 18 Glud1
Tg and 15 wt mice; middle-aged, 13–17.5 month old, 8 Tg and 15 wt mice; and old, 18–22.5
month old, 15 Glud1 Tg and 12 wt mice. Among the three age groups, only three mice from
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the 13–17.5 month-old group were scanned longitudinally, i.e., at the 13–17.5 and the 18–
22.5 month-old period.
Magnetic Resonance Spectroscopy Measurements of Neurochemicals in the Hippocampus
and Striatum
The 1H MRS data were acquired from the hippocampus and striatum of Glud1 Tg and wt
mice using a 9.4 T MR system (Agilent Technology, Santa Clara, CA). The 1H MRS scans
were performed on these mice at the three aforementioned age ranges: adult, middle aged,
and old mice from volumes of 4–6 μl using a spin echo, full-intensity acquired localized
spectroscopy sequence (echo time 3 ms; repetition time 4 s) [44]. The in vivo 1H MR spectra
were acquired from the voxels located in the left hippocampus and the striatum. The voxel
size of the hippocampal VOI was 2.2 × 1.2 × 2.4 mm3; and hippocampal tissues were
estimated to be over 80 % in a given VOI. The voxel size of the striatal VOI was 1.7 × 1.8 ×
2.0 mm3 and included mainly striatal tissues (over 95 % in a given VOI). During MRS
scans, the animals were anesthetized using a gas mixture of 1:1 air:oxygen with 1–1.5 %
isoflurane. Their core temperature maintained at 37 °C. Magnetic field homogeneity was
optimized using FASTMAP, a fast automatic shimming technique [45]. Concentrations of
19 neurochemicals were quantified using an MRS data analysis package, LCModel (linear
combination of model spectra of metabolite solutions in vitro) software [46].
Statistical Analyses
Neurochemical levels were compared cross-sectionally among three age groups (8–12.5 vs.
13–17.5 months and 8–12.5 vs. 18–22.5 months) and two genotypes (only for 8–12.5
months) using two-sample t tests. The p values from the independent t tests were adjusted
for multiple comparisons with the false discovery rate (FDR) correction using the fdrtool
package [47] in R software [48]. Mean differences with FDR-adjusted p values of <0.05
were considered significant.
Results
In Vivo Metabolic Differences Between Glud1 Tg and wt Mouse Hippocampus and Striatum
In order to assess the effects that overexpression of Glud1 in CNS neurons may have on the
biochemical state in the brains of living Glud1 Tg mice, we employed 1H MRS to measure
the levels of 20 metabolites in wt and Glud1 Tg mouse hippocampus and striatum (Fig. 1a,
b). These measurements included neurochemicals that may be related to Glu metabolism,
such as glutamine (Gln), aspartate (Asp), γ-aminobutyric acid (GABA), N-acetylaspartate
(NAA), and N-acetylaspartylglutamate (NAAG). In the present study, 1H MRS
measurements were focused on equal volumes of tissue (voxels) in the hippocampus and
striatum regions of wt and Glud1 Tg mice. These two regions were selected because they
exhibit decreases in MAP2-labeled dendrites and dendritic spines, as well as decreases in
synaptophysin-labeled nerve terminals in the Glud1 Tg compared with wt mice [38].
Furthermore, the morphological changes in the hippocampus become progressively and
significantly greater as the Glud1 Tg mice age [38]. 1H MRS measurements were performed
in three age ranges: adult (8–12.5 months), middle aged (13–17.5 months), and old (18–22.5
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months) mice. The brain is fully developed at 8 months and the transgene-related neuronal
damage in the hippocampus is clearly discernible at that age [38].
We previously reported on the differences in the concentrations of a few neurochemicals
between Tg and wt mouse brain in a relatively small population of 9 month old mice [38].
Here, we first describe the results of neuro-chemical measurements obtained using a larger
group of 8–12.5 month old Tg and wt mice. In this adult group, we detected five
neurochemicals whose levels were significantly elevated in the hippocampus of Tg as
compared with wt mice (Fig. 2a). These were Glu (p = 0.05), phosphocreatine (PCr) (p =
0.03), glucose (Glc) (p = 0.02), glutathione (GSH) (p = 0.03), and NAA (p = 0.02). The
levels of the combined NAA and NAAG (NAA + NAAG) (p = 0.02) were also significantly
elevated in the Tg as compared with wt hippocampus. This difference in NAA plus NAAG
might have been primarily due to the elevation of NAA since the NAAG levels did not
differ between wt and Tg (Fig. 2a). There was only one metabolite that was at significantly
(p = 0.02) lower levels in the Tg compared with the wt hippocampus, lactic acid (Lac). The
levels of the remaining metabolites did not differ significantly between Tg and wt mice.
In the striatum of adult Tg mice, the levels of four neuro-chemicals including those of the
combined NAA + NAAG, were significantly higher than those measured in wt striatum (Fig.
2b). These were: Glu (p = 0.04), NAA (p = 0.05), NAA + NAAG (p = 0.04), and taurine
(Tau) (p <0.01). Thus, the levels of Glu, NAA, and NAA + NAAG were differentially
elevated in both hippocampus and striatum of the Tg mice. Also in the striatum, the levels of
six metabolites were significantly lower in Tg than those in wt mice. These neurochemicals
were: aspartate (Asp) (p = 0.04), GABA (p = 0.02), Lac (p = 0.04), myo-inositol (mI) (p =
0.05), NAAG (p = 0.01), and serine (Ser) (p = 0.01). The only neurochemical that was
consistently lower in both hippocampus and striatum was Lac.
The significantly higher levels in Tg versus wt mice of GSH, PCr, NAA, NAA + NAAG,
and Glc in the hippocampus, and of NAA, NAA + NAAG, and taurine in the striatum,
represent new observations, as were also the lower levels of Lac in both hippocampus and
striatum, and of GABA, mI, Ser and NAAG in the striatum only in Tg mice. However, the
metabolic profiles of wt and Tg mouse hippocampus and striatum at a single age represent
only a snapshot of what may be a progressive, aging-related, differential change in the
metabolic activity in the brains of these two genotypes of C57BL/6 mice.
Age-Related Changes in Neurochemical Levels in Glud1 Tg and wt Mouse Hippocampus
and Striatum
To explore possible age-associated changes in the levels of the metabolites we detected in
hippocampus and striatum, we performed in vivo MRS measurements in adult, middle-aged,
and old-aged Tg and wt mice. Eight neurochemicals, including NAA + NAAG, increased
significantly with advancing age in the hippocampus of Tg mice and two neurochemicals,
alanine (Ala) and Asp, had age-related decreases (Fig. 3a, b). In the wt mouse hippocampus,
the levels of eight neurochemicals changed significantly with advancing age. Of these, the
levels of six increased and those of two, Ala and Asp, decreased significantly with
advancing age (Fig. 3c, d). Similarities in age-related changes in the levels of
neurochemicals in the hippocampus of both Tg and wt mice included increases in creatine
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(Cr), phosphorylcholine, (PCho), Glc, mI, and NAAG, and decreases in Ala and Asp (Fig.
3). Particularly noteworthy differences between Tg and wt hippocampus levels during aging
were those for Gln and the ratio of Gln to Glu (Gln/ Glu), both of which increased in the
hippocampus of the Tg mice (p ≤ 0.023 and p ≤ 0.04, respectively). The amino acids Gln
and Glu are linked in terms of metabolic inter-conversions of Glu to Gln in glial cells and of
the reverse in glutamatergic neurons, thus the age-associated elevations in Gln and the
Gln/Glu ratio may represent a characteristic change of the aging process in the hippocampus
of Glud1 Tg mice.
There were several common changes in the levels of neurochemicals across age in the
striatum of wt and Tg mice. These included significant decreases with advancing age in
three neurochemicals: Asp, GABA, and GSH, and significant increases in five
neurochemicals: Gln, mI, NAA, NAAG, NAA + NAAG (Fig. 4a, b). The Glu levels in the
striatum increased with age only in the Tg mice, whereas those of Gln increased in both the
wt and Tg striatum (Fig. 4).
Discussion
The studies described above represent a unique in vivo neurochemical investigation
covering the age span from adulthood to old age in two important brain regions, the
hippocampus and striatum, and in two mouse genotypes, the Glud1 Tg and the respective wt
C57BL/6 cohorts. The 1H MRS assessment in two brain regions of the Tg and wt mice has
identified both aging-related metabolic changes, as well as changes in brain neurochemicals
resulting from glutamatergic and GDH hyperactivity in the Glud1 mouse brain. The present
study of aging-related changes in the brain was initiated using adult Tg and wt mice, 8–12.5
months-old, in order to avoid possible confounding effects of early developmental
influences resulting from the expression of the transgene.
In the adult mice, we replicated the previous observations of elevated Glu levels in
hippocampus and striatum [38]. In terms of the overall metabolic status of the Glud1 mice as
judged from the different levels of the neuro-chemicals examined in the present study, two
of the differences that we detected were particularly interesting. The first was the
significantly higher levels of GSH in the Tg as compared with the wt mouse hippocampus,
and the second was the significantly lower levels of Lac in both hippocampus and striatum
of the Tg than those of the wt mice.
A possible interpretation of the origin and relevance of these two specific neurochemical
differences between wt and Tg hippocampus and striatum might be that the elevated levels
of GSH and the lower levels of Lac in Tg versus wt mice were indicative of alterations in
the astrocyte–neuronal shuttle of metabolites that has been described in relationship to
neuronal activation and the release of Glu into the synapse [49, 50]. The release of Glu by
neurons activates the synthesis of GSH and enhances the activity of the glycolytic pathway
in astrocytes [49]. The former action of Glu leads to increases in GSH formation in
astrocytes, while the activation of the glycolytic pathway leads to increased formation of
Lac by astrocytes. Increases in GSH levels might represent an adaptive response as GSH
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leads to enhanced protection of neurons from excess oxidative stress initiated by Glu
receptor stimulation [2, 9, 51].
The increased formation of Lac in astrocytes leads to Lac release by astrocytes and the
uptake of Lac by activated neurons. The neuronal uptake of Lac averts the induction of
neuronal oxidative stress that occurs when glycolysis is the sole source of energy production
in neurons [49, 52]. The Lac taken up by neurons is converted to pyruvate which provides
the substrate for oxidative phosphorylation in neurons with high energy demands. It is
possible that the expression of the Glud1 transgene in neurons of the Tg mice leads to
increases in mitochondrial metabolism and in the overall metabolic capacity of mitochondria
in the Tg hippocampus and striatum. Thus, the lower Lac levels in the hippocampus and
striatum of the Glud1 Tg mice might be an indication of higher rates of utilization of Lac by
brain neurons because of their greater mitochondrial capacity than those of wt mice, or an
indication of a Glu-induced hyper-active state of neurons in the brain of the Tg animals. The
latter interpretation would be consistent with the previously reported switch from Glc-
dependent glycolysis to Lac-dependent energy generation in neurons that are stimulated by
excess Glu [49, 50]. We are currently exploring the possibility that there may also be a
differential metabolic capacity of mitochondria isolated from three different regions of Tg
and wt mouse brains.
The rationale for studying metabolite changes in two brain regions was based on our past
observations that neurons in adjoining regions of the brain may differ very significantly in
terms of gene expression patterns and in their vulnerability to metabolic and oxidative stress,
including the stress brought about by the aging process [38, 39, 51, 54–57]. Furthermore, it
has previously been shown that the levels of Glu, Gln, GABA and Asp may vary by a factor
of five and up to a factor of 21 in different regions of rat brains, and that the effects of aging
on the levels of these amino acids are not identical across various rat [58] or mouse brain
regions [59]. Thus, we anticipated that we might observe some differences between
hippocampus and striatum with regard to both baseline levels and aging-related changes in
the levels of Glu, Gln, Asp and other neurochemicals measured in the hippocampus and
striatum.
An interesting finding in the present study was that hippocampal Lac concentrations were
consistently lower than those in the striatum of both wt and Glud1 Tg mice. This was true
for both the measurements obtained with adult mice as well as those with mice at
progressively older ages. Others have shown that the hippocampus has lower concentrations
of Lac than either cerebral cortex or striatum [60]. One possible explanation for these
observations might be that the lower Lac concentrations indicate high utilization of Lac for
energy generation by hippocampal neurons, a region of the brain with a large population of
glutamatergic innervation.
Another consistent observation in the present study was that of higher NAA levels in adult
Tg hippocampus and striatum compared with those in wt mice. This was unexpected in light
of our observation of neuronal damage in the hippocampus of the Tg mice at that age [38]
and evidence that NAA levels are lower in the presence of damaged neurons, both in
humans and animals [61–64]. A likely explanation for the elevations in NAA concentrations
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in the Tg mouse brain is that NAA concentrations are the result of increased neuronal and
mitochondrial activity in the Glud1 Tg mice [65]. Mitochondrial Glu metabolism leads to
the synthesis of Asp as part of transamination reactions and this feeds into the synthesis of
NAA [66–68]. However, changes in the levels of Asp may differ from those of NAA as Asp
is involved in cytoplasmic and intramitochondrial transamination reactions that are linked to
both the tricarboxylic acid cycle and the urea cycle. Thus, changes in Asp levels are not
determined only by the activation of the NAA and NAAG synthetic pathways. Nevertheless,
even though it would be difficult to pinpoint the reasons for the direction of changes in Asp
levels with advancing age, our observation of consistent age-related decreases in Asp levels
in both wt and Tg hippocampus and striatum fits with previous observations of such aging-
associated decreases in the brains of senescence accelerated mice [69].
With regard to the aging process, there were only a few consistent age-associated
neurochemical changes that might be considered as possible markers of the aging process in
both the hippocampus and striatum of wt and Tg mice. The decline of Asp and the increase
in NAAG levels in both brain regions and in both genotypes, might be considered as in vivo
neurochemical markers of the effects of the aging process in the hippocampus and striatum.
The significant increases in NAAG concentrations during aging represent an intriguing new
observation. It is possible that the aging process in both wt and Tg hippocampus and
striatum, led to the progressive activation of the NAAG biosynthetic pathway. NAAG has
been shown to function as a neurotransmitter or neuromodulator in the CNS acting pre-
synaptically to decrease the release of Glu from nerve endings [61, 70]. As already pointed
out in preceding sections, brain aging is associated with both higher levels of depolarization-
induced release of Glu and diminished Glu re-uptake [14–16, 69]. Even though the
mechanism for the increases in NAAG levels in the brain is not known at this time, the
higher NAAG levels may modulate Glu release during brain aging and dampen the Glu-
initiated stimulation of neurons. Thus, NAAG may play a significant role in maintaining the
neurons of Tg and wt mice alive as an organism ages.
With regard to possible differential effects of the aging process on the brains of the Glud1
Tg as compared with the wt mice, there was a more consistent effect of aging on the levels
of Glc, Gln, Glu, and the ratio of Gln/Glu in the Tg than in the wt mice, especially in the
hippocampus region. The increases in the brain levels of Glc may be a sign of diminished
Glc utilization which would be consistent with observations of reduced Glc metabolic rates
in human brain during aging, especially in the frontal and temporal cortex [71, 72]. Such
decreases in Glc metabolic rates may result from either cell damage or from shifts in the use
of Lac in place of Glc as substrate for oxidative phosphorylation in hyper-activated neurons
of the Tg mouse brains. Both possibilities are likely in the Glud1 Tg mice. In addition, the
differential aging-related changes in Gln, Glu, and Gln/ Glu ratios in Tg versus wt mice,
may also be signs of an acceleration of age-associated neurodegenerative processes in the Tg
mouse hippocampus and striatum. We base this idea not only on our previous observations
of an accelerated loss of dendrites during aging in the hippocampus of Tg as compared with
wt mice [38, 39], but also on the fact that in another model of accelerated aging that occurs
in the absence of a disease, the senescence accelerated mouse model, both Glu and Gln brain
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levels are higher in the “senescence prone” as compared with the “senescence resistant”
mice [73, 74].
In the preceding paragraphs, we drew comparisons between the data we obtained using
MRS measurements and some data from the literature obtained by direct biochemical or
immunochemical analyses. We recognize the differences in the mode of gathering these data
and of some of the limitations of the approach that was used in the present study. For
example, the use of anesthesia during MR scans may present a confounding as it may alter
the levels of some neurochemicals, such as those of Lac. However, the observed differences
in the levels of brain neurochemicals among genotypes and age groups would still be valid
as all animals were scanned under the same conditions of light anesthesia (isoflurane at 1–
1.5 %). A second limitation of our studies might be related to the voxel definition of the
MRS volumes of the hippocampus. It is estimated from the anatomical MR images that the
hippocampal VOI contains up to about 15–20 % of non-hippocampal tissue, including white
matter and cortical and deep gray matter. The inclusion of components of these regions was
necessitated by the requirement of a rectangular shape for the definition of the voxels for the
MRS measurements of the hippocampus, a brain region with a three-dimensional curvilinear
structure.
We believe that the studies described in this report provide the background for future
directed explorations into the biochemistry of the brain during aging and under the influence
of excess Glu activity. Studies of the protein levels and activity of relevant enzymes, such as
the two isoforms of lactate dehydrogenase, NAAG synthetase, and monocarboxylic acid
transporter, as well as direct measurements of mitochondrial enzyme activities, would be
informative in developing a mechanistic understanding of the neurochemical changes
observed in the present study.
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a Representative in vivo 1H MR spectra acquired from the hippocampus of Glud1 transgenic
(Tg, top) and wild type (wt, bottom) mice. b Representative in vivo 1H MR spectra acquired
from the striatum of Tg (top) and wt (bottom) mice. Neurochemical abbreviations are
alanine (Ala), aspartate (Asp), ascorbate (Asc), choline (Cho), creatine (Cr), γ-aminobutyric
acid (GABA), glucose (Glc), glutamate (Glu), glutamine (Gln), glutathione (GSH),
glyceropho-sphoryl-choline (GPC), phosphorylcholine (PCho), myo-Inositol (mI), lactate
(Lac), N-acetylaspartate (NAA), N-acetylaspartylglutamate (NAAG), phosphocreatine
(PCr), phosphorylethanolamine (PE), and serine (Ser)
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Comparison of neurochemical profiles of adult (8–12.5 month-old) Tg and wt mice. The
profiles consist of the concentration of 19 metabolites measured from the hippocampus (top)
and striatum (bottom) using in vivo 1H MRS. The calculated ratio of Gln to Glu
concentration in Tg and wt hippocampus and striatum is shown on the right hand side of
each panel, and the numerical values for this ratio are shown on the right ordinate. The
symbols (single asterisks) and (double asterisks) indicate levels of significance in the
differences between Tg and wt hippocampus and striatum: *0.01 <p <0.05; **p <0.01
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Effects of the aging process on the concentration of neuro-chemicals in the hippocampus of
Tg (a, b) and wt (c, d) mice. The concentrations of some of the amino acids as well as the
ratio of Gln to Glu concentrations are shown in b and d. In b and d, the right hand ordinate
shows the numerical values of the Gln to Glu ratios. The age groups of the Tg and wt mice
were 8–12.5, 13–17.5, and 18–22.5 months old as indicated in the figures. The group size
for Tg and wt mice at each age are described in the “Methods” section. Statistical
comparisons were between the concentration values for the 13–17.5 or the 18–22.5 month-
old mice and those of the 8–12.5 month-old mice. The symbols (single asterisks) and
(double asterisks) indicate statistically significant differences with p values of 0.01 <p <0.05
and p <0.01, respectively
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Effects of the aging process on the concentration of neuro-chemicals in the striatum of Tg
(a, b) and wt (c, d) mice. The data were obtained from the same groups of mice as those
shown in Fig. 3 and the symbols and statistical comparisons were the same as described in
the legend of Fig. 3
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